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Abstract
Every year, a small number medicinal products receive marketing authorisation or a product
licence. However, in their wake several thousand drug candidates fall by the wayside. The
discovery and development journey through to the approval and marketing stages of these
successful candidates as we know it can take over 12 years and often much longer and costs
approximately $2.6 billion (Sullivan, 2019).
Prior to the regulatory authorities granting a marketing authorisation or product licence, the
sponsor is required to provide a dossier that includes relevant administrative, quality,
nonclinical and clinical data. In addition, both the EU and US regulatory bodies require
preclinical testing of the drug to be marketed and three clinical trial phases among the drug
development process. These are lengthy, complex processes and in most cases patient access
to medicines in a timely manner is very challenging.
With this in mind, both the EU and US regulatory authorities have adopted new initiatives
which aim to make the availability of certain therapies accessible to patients in an expedited
manner. Many of these initiatives focus on therapies that address unmet clinical needs. These
initiatives are also available for many Advanced Therapy Medicinal Products (ATMPs).
However, as of October 2020, only 15 ATMPs have been approved in the EU in the last decade
with five of them withdrawn from the market. In addition, only 14 such therapies have been
approved in the US.
There have been some improvements since the commercialisation of the first ATMP yet many
hurdles remain which have limited and will continue to limit the availability of safe, efficacious
high quality products in a timely manner to patients in much need of these promising
therapies.
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1. Introduction
Every year, several medicinal products receive marketing authorisation or a product licence.
For example in 2018, 103 novel therapies were approved in the EU (44 therapies) and US (59
therapies) (Leitgeb, 2019, BioPharm International, 2020). Meanwhile, 48 therapies were
approved in the US in 2019 compared to 66 therapies receiving a positive opinion in the EU
(Kashoki et al., 2020,)
However, in their wake several thousand drug candidates fall by the wayside. The discovery
and development journey through to the approval and marketing stages of these successful
candidates as we know it can take over 12 years and often much longer and costs
approximately $2.6 billion (Sullivan, 2019).
Prior to the regulatory authorities granting a marketing authorisation or product licence, the
sponsor is required to provide a dossier that includes relevant administrative, quality,
nonclinical and clinical data. In addition, both the EU and US regulatory bodies require
preclinical testing of the drug to be marketed and three clinical trial phases among the drug
development process. These are lengthy, complex processes and in most cases patient access
to medicines in a timely manner is very challenging. With this in mind, both the EU and US
regulatory authorities have adopted new initiatives which aim to make the availability of
certain therapies accessible to patients in an expedited manner, Many of these initiatives
focus on therapies that address unmet clinical needs. These initiatives are also available for
many Advanced Therapy Medicinal Products (ATMPs).
This paper will review and compare the EMA (European Medicines Agency) and FDA (Food
and Drug Administration) approval pathways for ATMPs. It will also access whether these
initiates are fit for purpose for such therapies
ATMPs are a fast-growing field of novel therapies which have shifted the traditional strategy
of “one-size fits all” to a more personalised medicinal approach. Cell therapies (discussed
below), for example, can be allogeneic (universal) therapies where the therapy is dependent
on a single source of cells (donor) to treat several patients. To date many of the approved cell
therapies have been autologous, where the cells are derived from the patient, modified,
expanded and used to treat the same patient. (Farid and Jenkins, 2018, De Riva, 2020).
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ATMPs offer revolutionary new prospects for the treatment of diseases and injuries such as
Alzheimer's disease, cancer and muscular dystrophy and have huge potential for the future
of medicines. ATMPs fall under the regulatory framework of biological medicines. In the EU,
these therapies encompass gene therapy medicinal products (GTMPs), tissue-engineered
products (TEPs) and cell-based therapy medicinal products (CTMPs).

Figure 1. Cell Therapy Generation Process ((modified from) De Riva, 2020)

It is worth noting that the subclassification of ATMPs in the EU differ from those in the US. In
the EU, the ATMP subclassification consists of four groups (somatic cell therapies, genre
therapies, tissue engineered therapies and combination therapies) while that in the US
consists of two subclassification which are cell therapies and gene therapies. (US FDA, 2019).
In the US, these therapies are generally referred to as cell and gene therapies (CGT) while in
the EU they are referred to as ATMPs. However, in both territories, these therapies fall under
the regulations of biologics (Iglesias-Lopez et al., 2019). An ATMP that integrates a medical
device, is referred to as a combination therapy (cATMP) (Regulation (EC) No 1394/2007,
Iglesias-Lopez et al., 2019).
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ATMPs are defined in “section 506(g)(8) of the FD&C Act as including cell therapies,
therapeutic tissue engineering products, human cell and tissue products, and combination
products using any such therapies or products, except for those regulated solely under section
361 of the Public Health Service Act (PHS Act) (42 U.S.C. 264) and Title 21 of the Code of Federal
Regulations Part 1271 (21 CFR Part 1271)” (FDA and CBER, 2019).

Figure 2. Regenerative medicines (modified from Gross, 2017).

2. Regulatory Framework
Advanced therapies were introduced into EU legislation as a new classification of biological
medicinal products in 2003 through Directive 2003/63/EC, amending Directive 2001/83/EC.
Meanwhile, the first EU wide regulatory framework relating to ATMPs Regulation 1394/2007
amending both Directive 2001/83/EC and Regulation (EC) No 726/2004 entered into force on
30 December 2007 and applied from 30 December 2008. Other Directives/Regulations
relating to ATMPs include Directive 2009/120/EC of December 2009 relating to medicinal
products for human use as regards advanced therapy medicinal products (and amending
Directive 2001/83/EC), Regulation 726/2004/EC community procedures for the authorisation
and supervision of medicinal products for human and veterinary use) (Eder and Wild, 2019).In
the US the legal framework for biological products relating to ATMPs includes the regulation
for biologics under section 351 of the Public Health Services Act (PHSA) and the Federal Food,
Drug, and Cosmetic Act (FD&C Act) as well as Title 21 of the US Code of Federal regulation
(CFR) 600 – 680 and also 21 CFR 1271. In addition, in December of 2016, section 506 of the of
the FD&C Act of the 21st Century Cures Act was amended by adding a new section (section
30330) which explicitly addresses the expedited development and review of some
4
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regenerative medicine therapies designated as Regenerative Medicine Advanced Therapy
(RMATs) (US Congress.Gov - 21st Century Cures Act, 2016).
In some cases, the approval process of a novel medicinal product is expedited. In the US this
occurs through one of FDA’s expedited programmes, such as the Fast Track Designation
scheme and in the EU through pathways such as the Priority Medicine Designation Scheme
(Smith, 2017, FDA, 2017). This expedited development pathway only applies to certain
therapies which treat severe or life-threatening illnesses and are considered to offer
therapeutic benefit over current approved medicines. Advanced therapies typically meet
these criteria. The approval pathway depends on the medicine’s characteristics and the target
patient population (Detela and Lodge, 2019a).
In the US, the FDA launched the Fast Track Designation (FTD) and Breakthrough Therapy
Designation (BTD) while in the EU, the Priority Medicines (PRIME) Designation scheme was
launched and prior to that, the adaptive pathway which was formerly known as ‘Adaptive
Licensing’ (FDA, 2014, EMA, 2016, Article 14(8) of Regulation (EC) No 726/2004, EMEA, 2005,
(Gannedahl, Udechuku and Bending, 2018). In addition to this, in the EU, other options are
available for ATMPs which includes Orphan Designation, Compassionate Use and Hospital
Exemption. A hospital exemption (HE) is granted on a non-routine basis. It permits the use of
an ATMP in the EU member state’s territory without the need for a marketing authorisation.
This exception only applies to custom made therapies in hospital settings and only in certain
circumstances where a patient is in much need of a treatment and where no medicines are
currently available particularly in areas of high unmet medical need. If such therapies are
granted a HE, they still need to comply with the same requirements that apply to authorised
medicinal products in regard to quality, traceability as well as pharmacovigilance (Medicines
Agency, 2016, Yano and Yamato, 2018).
•

Fast Track Designation (FTD)

This program was developed to expedite the development and review process of medicines
intended for serious or life-threatening conditions, where clinical or non-clinical data indicate
these medicines fill an unmet medical need (FDA, 2014).
Fast track drugs are potentially eligible for the Accelerated Approval and Priority Review
schemes. Accelerated Approval is a scheme established for therapies that are intended for
5
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serious conditions and that cater for an unmet medical need. They must also demonstrate
their effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit or on
a clinical endpoint (Accelerated Approval | FDA, 2018).
In addition, it is designed for illnesses where the disease course is long, and an extended
period would be required to measure the intended clinical benefit of the drug. Developers of
such therapies are permitted to market their product while continuing to conduct
confirmatory studies to obtain full marketing approval (Gault, 2015). On the other hand,
Priority Review expedites the therapy’s approval process from the standard ten months to six
months (Gault, 2015).
•

Breakthrough Therapy Designation (BTD)

This program was developed to expedite the development and review process of medicines
for serious or life-threatening conditions with primary evidence of considerably enhancing at
least one clinically significant endpoint over current available medicines (FDA, 2014).
Breakthrough therapies are entitled to fast track benefits as well as priority review and
accelerated approval.
•

Regenerative Medicine Advanced Therapy (RMAT)

According to section 3033 of the 21st Century Cures Act, a drug is eligible for RMAT designation
if:
a. The drug is a regenerative medicine therapy, which is defined as a cell therapy,
therapeutic tissue engineering product, human cell and tissue product, or any
combination product using such therapies or products, except for those regulated
solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code
of Federal Regulations;
b. The drug is intended to treat, modify, reverse, or cure a serious or life-threatening
disease or condition; and
c. Preliminary clinical evidence indicates that the drug has the potential to address unmet
medical needs for such disease or condition.
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These therapies are eligible for the expedited programs, comprising Breakthrough Therapy
Designation, Fast Track Designation, RMAT Designation, Priority Review Designation and
Accelerated Approval (FDA, 2019). A medicine that obtains RMAT designation may be eligible
for priority review if it meets the criteria at the time of marketing application submission.
Furthermore, therapies that receive RMAT designation may be offered accelerated approval
(FDA, 2019).

•

PRIority Medicines (PRIME) Designation

This program was developed in 2016 and was intended to enhance the support given for the
development of medicines that target an unmet medical need. It uses processes that were
already part of the regulatory framework such as accelerated assessment, conditional
approval, and scientific advice. It was also designed to initiate early dialogue between the
EMA and the therapy developer (FDA, 2014). Medicines under this scheme are usually
granted Accelerated Assessment. This assessment is a process that reduces the time required
for an application to be reviewed (150 from the standard 210 days).

•

Conditional Marketing Authorisation (CMA)

This scheme was developed for medicinal products with promising, yet incomplete efficacy
data are granted market authorisation on the condition that they are further evaluated while
on the market (Gulfo, 2016, Bonnano, et al., 2017). In addition, specific obligations are
mandatory with regard to collection of pharmacovigilance data (EMEA, 2005, Troncoso and
Diogene, 2014, Godman et al., 2015). However, the authorisation is not intended to remain
conditional indeterminately. The CMA is only effective for one year. Upon review of
information collected during the conditional approval period, these medicinal products may
be withdrawn from the market, granted traditional standard approval or continue to be
marketed conditionally, depending on the data collected during that period (Gulfo, 2016). The
CMA scheme was launched in 2006, however it was later integrated within PRIME
(Antoñanzas, Juárez-Castelló and Rodríguez-Ibeas, 2018).
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Authorisation Under Exceptional Circumstances (ECMA)

A marketing authorisation under exceptional circumstances is only applicable to therapies
that cannot obtain a standard marketing authorisation as the required safety and efficacy
data cannot be provided due to the disease being so rare or because a clinical endpoint is
challenging to measure due to ethical or scientific reasons (EMA, 2005, Nicotera et al., 2019).
Since it is not possible for these therapies to obtain a standard MA, an ECMA is granted on
the basis that the applicant agrees to continuously monitor product safety and reports any
product incidents to the competent authorities. After an ECMA is granted it is valid for five
years with annual re-assessment procedures performed. Generally, therapies licenced
through this scheme would have an orphan drug designation. However, orphan drugs are only
eligible for the ECMA designation if they meet the criteria of same (Detela and Lodge, 2019b).

Table 1. Overview of US Expedited Pathways (FDA, 2014, EFPIA, 2016)
Fast Track

Breakthrough

Accelerated

Therapy

Approval

Priority Review

Regenerative
Medicine
Advanced
Therapy

Nature of Program

Designation

Designation

Approval Pathway

Designation

Designation

Year Introduced

1997

2012

1992

1992

2016

Qualifying Criteria

A drug that is

• A drug that is

• A drug that treats

• An application

A drug is a

intended to treat a

intended to treat a

a serious condition

(original or efficacy

regenerative

serious condition

serious condition

AND generally

supplement) for a

medicine

AND nonclinical or

AND preliminary

provides a

drug that treats a

therapy, AND

clinical data

clinical evidence

meaningful

serious condition

the drug is

demonstrate the

indicates that the

advantage over

AND, if approved,

intended to

potential to address

drug may

available therapies

would provide a

treat, modify,

unmet medical need

demonstrate

AND demonstrates

significant

reverse, or

OR

substantial

an effect on a

improvement in

cure a serious

• A drug that has

improvement on a

surrogate endpoint

safety or

condition,

been designated as

clinically significant

that is reasonably

effectiveness OR

AND

a qualified

endpoint(s) over

likely to predict

• Any supplement

preliminary

infectious disease

available therapies

clinical benefit or on

that proposes a

clinical

a clinical endpoint

labelling change

evidence

that can be

pursuant to a report

indicates that

measured earlier

on a paediatric

the drug has

than irreversible

study under 505Ab

the potential

morbidity or

OR • An application

to address

product
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mortality (IMM) that

for a drug that has

unmet

is reasonably likely

been designated as

medical

to predict an effect

a qualified

needs for

on IMM or other

infectious disease

such disease

clinical benefit (i.e.,

products OR

or condition

an intermediate

• Any application or

clinical endpoint)

supplement for a
drug submitted with
a priority review
voucher

Timeline for

• Within 60 calendar

Within 60 calendar

Within 60 calendar

• Within 60

response

days of receipt of

days of receipt of

days of receipt of

calendar days

the request

the request

original BLA, NDA,

of receipt of

or efficacy

the request

Not specified

supplement
Features

• Actions to

All fast track

Approval based on

• Shorter clock for

• All

expedite

designation

an effect on a

review of marketing

breakthrough

development and

features, including:

surrogate endpoint

application (6

therapy

review

 Actions to

or an intermediate

months compared

designation

• Rolling review

expedite

clinical endpoint

with the 10-month

features,

development and

that is reasonably

standard review)

including

review

likely to predict a

early

 Rolling review

drug’s clinical

interactions

• Intensive guidance

benefit

to discuss any

on efficient drug

potential

development,

surrogate or

beginning as early as

intermediate

Phase 1

endpoints •

• Organisational

Statute

commitment

addresses

involving senior

potential

managers

ways to
support
accelerated
approval and
satisfy postapproval
requirements
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Table 2. Overview of EU Expedited Pathways (EMA, 2016, Early access, Valid Insight, 2016, EFPIA, 2016)
Conditional Marketing

Authorisation Under

Application

Exceptional

PRIME

Accelerated
Assessment

Circumstances
Nature of Program

Expedited Development

Expedited Development

Early dialogue with

Expedited Review

product developer

Year Introduced

2005

1993

2016

2005

Qualifying Criteria

Intended for serious

Intended for when data on

Intended for therapies

Intended for

life-threatening or

safety and efficacy is not

that may have the

therapies that are of

debilitating diseases OR

possible due to

potential to address an

interest to the public

For use in emergency

information not being

unmet medical need OR a

in so that they offer

conditions OR for

available or due to a rare

therapy that offers

innovative public

Orphan medicines

condition or unethical

significant advantages

benefit

Intended for medicines

reasons

through a significant

where benefit of their

enhancement of efficacy

availability outweighs
the risks of less
comprehensive data
than usually required
Timeline for

210

210

210

150 days instead of

Response
Features

210
•

Similar to FDA

Full safety and efficacy

Accelerated

data not required

Approval
•

•
•

Enables Accelerated
Assessment

Equivalent to FDA

Similar to FDA’s

Priority Review

May be eligible for

Breakthrough

expedited

Therapy Designation

assessment

3. ATMP Approvals in the EU and US
In 2009, ChondroCelect® was the first ATMP approved in the EU and is a TEP for the treatment
of cartilage defects (Kassim and Somerville, 2013). About a year later, the US approved its first
ATMP,PROVENGE®, a somatic cell therapy indicated for the treatment of certain prostate
cancers (European Medicines Agency, 2013). Meanwhile, Glybera® was the first gene therapy
approved in the EU in 2012 (European Medicines Agency, 2013). It should be noted that
several of the earliest approved ATMP therapies were later withdrawn from the market for
10
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various reasons. For example, after the expiry of Glybera’s marketing authorisation (MA) its
marketing authorisation holder did not apply for an MA renewal. The CEO of uniQure Matt
Kapusta, stated that “Glybera’s usage has been extremely limited, and we do not envision
patient demand increasing materially in the years ahead”(WARNER, 2017). ChondroCelect
was also withdrawn from the market in July 2016, at the request of the marketing
authorisation holder citing commercial reasons (EMA, 2019). Zalmoxis was also withdrawn
from the market with the MA holder stating that is has decided to permanently discontinue
the marketing of the therapy for commercial reasons(EMA, 2019).

Table 3. Current approved ATMPs in the EU as of October 2020 (KEGG DRUG: New Drug Approvals
in Europe, 2020) (European public assessment reports: background and context | European
Medicines Agency, no date).

Therapy Name

Licence Holder

Approval Date

ChondroCelect

TiGenix

Oct 2009 – Jul 2016

Glybera

UniQure

Oct 2012 – Oct 2017

MACI

Vericel

Jun 2013 – Sep 2014

Provenge

Dendreon

Sep 2013 – May 2015

Zalmoxis

MolMed

Aug 2016 – Oct 2019

Holoclar

Chiesi

Feb 2015

Imlygic

Amgen

Dec 2015

Strimvelis

GSK/Orchard Therapeutics

May 2016

Kymriah

Novartis Europharm Ltd.

Aug 2018

Luxturna

Spark Therapeutics Ireland Ltd.

Nov 2018

Spherox

CO.DON

Jul 2017

Yescarta

Kite Pharma EU

May 2018

Zolgensma

AveXis EU Limited,

May 2020

Zynteglo

Bluebird Bio

May 2019

Alofisel

Takeda/ TiGenix

Mar 2018
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Table 4. Current approved ATMPs in the US as of October 2020 (FDA, 2020).
Therapy Name
Allocord
Clevecord
Ducord
Gintuit
Hemacord
Imlygic
Kymriah
Laviv
Luxturna
MACI
Provenge
Tecartus
Yescarta
Zolgensma

Licence Holder
SSM Cardinal Glennon Children's Medical Center
Cleveland Cord Blood Center
Duke University School of Medicine
Organogenesis Incorporated
New York Blood Center, Inc
Amgen Inc.
Novartis Pharmaceuticals Corporation
Azficel-T
Spark Therapeutics, Inc.
Vericel Corporation
Dendreon Corporation
Kite Pharma, Inc.
Kite Pharma, Inc.
AveXis, Inc

Approval Date
May 2013
Sep 2016
Oct 2012
Mar 2012
Nov 2011
Oct 2015
Aug 2017
Jun 2011
Dec 2017
May 2019
Apr 2010
Jul 2020
Oct 2018
May 2019

Looking at the above tables (Table 3 and Table 4), only 15 ATMPs have been approved in the
EU in the last decade with five of them withdrawn from the market. Meanwhile, only 14 such
therapies have been approved in the US. In addition, the approvals in the two regions
somewhat differ from each other. One would ask, why is there only a limited amount of
approvals so far and also some withdrawals?
Generally, market withdrawal is due to product safety or for commercial reasons. For
example, Glybera (the first gene therapy to receive an MA in the EU) was withdrawn from the
market as its developers decided not to apply for MA approval due to Glybera’s commercial
failure in the EU. The developers also encountered difficulties getting the Glybera to the US
and hence it is not listed in table 4. Glybera had a market price of €1million and a very limited
target population. This added to its failure on the market as the governments were not
interested in paying for it (Cynober, 2020).
Moreover, the main challenges that have been shown to impede the approval process are
specifically safety and efficacy issues as well as hurdles related to product quality and/or
product scale-up.
Moreover, the main challenges that have been shown to impede the approval process are
specifically safety and efficacy issues as well as hurdles related to product quality and/or
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product scale-up. One of the EMA’s Committee for Advanced Therapies (CAT) initiatives it to
provide developers with quality data certification. This involves the scientific evaluation of a
product’s quality data and is set to identify any potential issues early in the development
process so that they can be addressed ahead of the submission of a MAA. However, this
quality certification is only available to developers who have a micro-, small-, or medium-sized
enterprise (SME) status. Hospitals, academia and other non-profit organisations do not hold
SME status and therefore, would not benefit from CAT’s certification process. This is a big
obstacle as these non-profit organisations generally tend to be the main ATMP sponsors
(Carvalho, Martins and Sepodes, 2019).
Even though the EU and US expedited pathways applicable to ATMPs offer additional
flexibility and the prospect for accelerated market authorisation they are still criticised as
being too complex and lengthy. They are also considered too ambiguous by non-profit
organisations and SMEs due to restricted regulatory oversight (Elsanhoury et al., 2017).
Furthermore, as mentioned earlier, a hospital exemption is a dedicated pathway available in
the EU that permits the use of unlicenced ATMPs in a member state’s territory without the
need for an MA. However, this pathway has its own limitations for example this pathway is
only available for custom-made products developed for individual patients (Cynober, 2020).
This option is only available for ATMPs prepare and administered in a hospital setting.
Moreover, under the HE these therapies can be administered to a patient even if there is an
alternative therapy available on the market (Houses of Parliament, 2017).
These HEs may encourage product developers not to apply for centralised marketing approval
and an HE might be seen to offer a more pragmatic option. However, not opting for the
central licencing route limits the availability of ATMPs to patients throughout the EU which
means less patients have access to them.
Currently, there is a push from organisations such as European Confederation of
Pharmaceutical Entrepreneurs (EUCOPE) to control the use of such exemptions and to
standardise/harmonise their use throughout the EU member states.(EUCOPE, 2020).
It is evident that more needs to be done to expedite the drug development, approval and
support processes so as to ensure more ATMPs are approved in a timely manner for patient
13
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access. In January of this year, the Alliance for Regenerative Medicine (ARM) published a
positioning paper outlining its recommendations on how the above raised question can be
addressed. These recommendations are:
•

“Establish a ‘one-stop shop’ ATMP coordination body at EU/EEA level to act as a broker
between the different stakeholders and facilitate cross-border patient treatment and
funding.

•

Create ‘one-stop shop’ ATMP coordination bodies in countries with regional funding or
with multiple payers/insurers to ensure authorities in the regions of treatment are
compensated for the costs of treating patients from other regions.

•

Encourage more effective coordination of HTA activities to ensure greater alignment
within Europe on product value assessment measures.”(The Alliance for Regenerative
Medicine, 2020).

In conclusion, ATMPs are complex and are costly to develop and manufacture. A high level of
expertise is required for their development. Having said they, these therapies present the
potential cures and not just treatment for diseases. Even though there have been some
improvements since the launch of the first ATMP, many regulatory hurdles remain which have
limited and will continue to limit the availability of safe, efficacious, high quality products in a
timely manner to patients in much need of these promising therapies. It is evident that the
regulatory framework is not best fit for purpose for ATMPs and that changes are needed to
streamline the availability of such therapies to patients. Some recommendations include the
following:
1. Harmonisation between the EU and the EU member states national competent
authorities.
2. Regional harmonisation between the EU and US regulatory bodies.

3. Establishment of a streamlined approval process
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4. The development of regulations with a focus on developing a practical risk-based
approach.

5. Streamlining and unifying the approval processes of ATMPs
6. Early support and communication between the regulatory authorities and all ATMP
developers and not just SMEs.

7. Harmonisation of the re-imbursements strategies available to ATMP developers on an
EU level as well as on a global level
8. Permitting the free movement of ATMPs within the EU.

9. Developing a “mutual recognition” approval pathway between the EU and other
regions that is applicable to ATMPs
10. Identifying the skills and expertise needed to develop and regulate ATMP and
fostering specialist centres and programmes to nourish and sustain these
requirements
The road to success is long, but vital to address the unmet needs of the patient.
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